Andrew Evans was retained on behalf of a joint defense group of insurers in a coverage dispute regarding the insurability and allocation of Syngenta Atrazine's settlements of class-action claims related to costs associated with monitoring and remediating the herbicide Atrazine in US community water systems. Syngenta is a global agriculture and biotechnology company. Mr. Evans provided testimony focusing on the portions of the Atrazine settlement that might be subject to coverage under certain insurance policies. His analysis included a series of potential alternative allocation scenarios.

The team

Related practices and specialties

Jump to Page

Get in touch.

Partner with a firm that delivers rigorous economic research and practical advice.